Fig. 2.
Fig. 2. Variations in Apaf-1 and procaspases in various pretreatment bone marrow samples. / (A) Aliquots containing 5 × 105 marrow mononuclear cells (at least 80% blasts) from patients with newly diagnosed AML (lanes 5-14) were subjected to SDS-PAGE, followed by blotting with reagents that recognize the indicated polypeptide. To provide a standard curve, aliquots containing 5 × 105, 2.5 × 105, 1.25 × 105, and 0.5 × 105 untreated HL-60 cells (lanes 1-4, respectively) were loaded onto each blot. The response of each patient to the first cycle of induction therapy is denoted above each lane as follows: − indicates NR; + indicates CR; 0 indicates UE. (B) Aliquots containing 5 × 105 mononuclear cells (lanes 5 and 7) or granulocytes (lanes 6 and 8) from the same AML marrows were analyzed as in panel A. Differential counts in each sample are indicated above each lane.

Variations in Apaf-1 and procaspases in various pretreatment bone marrow samples.

(A) Aliquots containing 5 × 105 marrow mononuclear cells (at least 80% blasts) from patients with newly diagnosed AML (lanes 5-14) were subjected to SDS-PAGE, followed by blotting with reagents that recognize the indicated polypeptide. To provide a standard curve, aliquots containing 5 × 105, 2.5 × 105, 1.25 × 105, and 0.5 × 105 untreated HL-60 cells (lanes 1-4, respectively) were loaded onto each blot. The response of each patient to the first cycle of induction therapy is denoted above each lane as follows: − indicates NR; + indicates CR; 0 indicates UE. (B) Aliquots containing 5 × 105 mononuclear cells (lanes 5 and 7) or granulocytes (lanes 6 and 8) from the same AML marrows were analyzed as in panel A. Differential counts in each sample are indicated above each lane.

Close Modal

or Create an Account

Close Modal
Close Modal